Linzi Horine
Family · Greensburg, INNPI 1285128454
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 33.5% of the total. 2025 is the largest year on record at $3,474, more than ten times the $130 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$969
- Takeda Pharmaceuticals U.S.A., Inc.$584
- Mallinckrodt Hospital Products Inc.$572
- Sanofi$423
- Verona Pharma, Inc.$316
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,04795%
- Education$3515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $2,480 |
| GSK | 62 | $969 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $584 |
| Mallinckrodt Hospital Products Inc. | 15 | $572 |
| Sanofi | 22 | $423 |
| Verona Pharma, Inc. | 15 | $316 |
| Grifols USA, LLC | 14 | $261 |
| Regeneron Healthcare Solutions, Inc. | 9 | $246 |
| Philips North America LLC | 11 | $198 |
| Insmed, Inc. | 12 | $180 |
| Amgen(2 entities) | 9 | $176 |
| Grifols Shared Services North America, Inc. | 2 | $167 |
| United Therapeutics Corporation | 7 | $166 |
| Mylan Specialty L.p. | 7 | $120 |
| Novartis | 7 | $105 |
| Boehringer Ingelheim | 5 | $85 |
| Viatris Specialty LLC | 5 | $83 |
| Merck | 3 | $60 |
| Vifor Pharma, Inc. | 3 | $53 |
| Electromed, Inc. | 5 | $41 |
| Johnson & Johnson | 1 | $39 |
| Pfizer | 1 | $26 |
| Octapharma USA, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,399 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 295 | $233,745 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 314 | $224,640 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $171,623 |
| TezspireTezepelumab-Ekko | 19 | $84,465 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 122 | $62,681 |
| Dupixent PenDupilumab | 12 | $45,513 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $24,310 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $24,066 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 269 | $7,602 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,911 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,581 |
| AirsupraAlbuterol Sulfate/Budesonide | 11 | $4,984 |
| Roflumilast | 56 | $2,898 |
| Theophylline ErTheophylline Anhydrous | 45 | $2,675 |
| Azelastine Hcl | 112 | $2,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Airsupra | $2,480 | $319,670365 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $969 | $282,121394 claims |
| Grifols USA, LLCProlastin C | $261 | $171,62311 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $85 | $69,592135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Greensburg
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.